Genetics & Genomics Frontiers — 2026-05-22

Key Highlights

Genome Editing Market on Track for $55.7 Billion by 2035

A market research report published May 21, 2026 by Healthcare Foresights projects the global genome editing market will reach USD 55.7 billion by 2035, growing at a compound annual growth rate (CAGR) of 17.4%. The analysis covers tools, technologies, and therapeutic applications across oncology, rare diseases, and agricultural genomics.

FDA Approves First ctDNA MRD-Guided Therapy

Among the most consequential regulatory actions indexed this week, the FDA approved the MRD-guided use of Genentech's Tecentriq in bladder cancer, paired with Natera's Signatera companion diagnostic (CDx). According to GenomeWeb, this marks the first FDA approval of a ctDNA MRD-guided therapy and the first agency approval of a blood-based MRD test as a CDx — a landmark for liquid biopsy-driven treatment decisions.

Guardant Health Upgraded CDx Wins FDA Approval

Guardant Health's upgraded companion diagnostic secured FDA approval this week. The blood-based test collects both genomic and epigenomic information to help guide treatment decisions in patients with advanced cancer, according to GenomeWeb.

Foundation Medicine Assay Approved as CDx for MET-Altered Lung Cancer

The FDA approved Foundation Medicine's tissue assay as a companion diagnostic for Tepmetko (tepotinib) in patients with MET-altered non-small cell lung cancer. Foundation Medicine had previously received CDx approval for its liquid-based FoundationOne Liquid CDx alongside the same drug.

Oxford Nanopore Teases Next-Generation Sequencing and Proteomics Roadmap

At its user meeting in London this week, Oxford Nanopore previewed upcoming products for RNA analysis, high-throughput sequencing, and proteomics. The UK company also shared longer-term R&D goals, including a new nanopore design and a pathway toward protein sequencing.

Personalis Secures Medicare Coverage for Breast Cancer MRD Test

Personalis announced this week that it has secured Medicare coverage for its MRD (minimal residual disease) test for breast cancer pre-surgical treatment monitoring — expanding reimbursed access to genomic surveillance tools in oncology.

QIAGEN Partners with NVIDIA to Integrate AI Into Bioinformatics

QIAGEN announced it will integrate NVIDIA computing and artificial intelligence into its bioinformatics platform, reflecting a broader industry trend of fusing genomics with large-scale AI infrastructure.

Proposed US Law Would Modernize CLIA and LDT Oversight

A newly proposed bill in the United States would update the Clinical Laboratory Improvement Amendments (CLIA) with new provisions for laboratory-developed test (LDT) oversight. The bill would provide tools to track LDT performance and validation, and affirm a 2025 court decision that LDTs are not subject to FDA oversight.

Blank Bio Raises $7.2M for RNA Foundation Model

Startup Blank Bio raised $7.2 million in seed funding for development of an RNA foundation model, signaling continued investor interest in AI-native genomics infrastructure.

Workforce Demand Grows as Genetics Reshapes Healthcare

A press release published May 22, 2026 highlights that as genetics and genomics become more central to clinical practice, demand is rising for professionals who can interpret complex genetic information. Southern California University of Health Sciences (SCU) cited this trend in announcing expanded training programs for genetic counselors and related professionals.

2 sources

globenewswire.com

globenewswire.com

ml.globenewswire.com

ml.globenewswire.com

Analysis

The Most Significant Development This Week: FDA's First ctDNA MRD-Guided Therapy Approval

The FDA's approval of Natera's Signatera as a companion diagnostic for Genentech's Tecentriq — specifically to guide MRD-based treatment decisions in bladder cancer — stands as the most structurally important development in genomics this week. Two "firsts" are embedded in one decision: the first approval of a ctDNA MRD-guided therapy, and the first blood-based MRD test approved as a CDx.

This matters because it validates a clinical framework that dozens of companies are building toward: using circulating tumor DNA to detect residual cancer after surgery, then triggering treatment decisions based on that molecular signal rather than on imaging or symptom recurrence. If this regulatory model holds, it could open a pathway for MRD-guided approvals across other cancer types — accelerating the shift from reactive to predictive oncology management.

The same week also saw Guardant Health's upgraded CDx — collecting both genomic and epigenomic data — receive FDA clearance, suggesting regulators are growing more comfortable with multi-modal molecular evidence in companion diagnostic approvals.

What to Watch

• LDT Legislative Progress: The proposed CLIA reform bill that would establish new LDT oversight provisions — and codify the 2025 court ruling limiting FDA jurisdiction — will be one to follow closely as it moves through Congress. Any change to this framework would affect hundreds of laboratories offering genomic tests.

• Oxford Nanopore Product Launches: Following its London user meeting preview, watch for formal product announcements in RNA analysis tools, high-throughput sequencing, and the company's longer-range proteomics roadmap.

• MRD-Guided Approval Cascade: With the Tecentriq/Signatera approval as a template, expect increased regulatory activity around ctDNA MRD tests in breast, colorectal, and lung cancer. Personalis's Medicare coverage win for breast cancer MRD monitoring suggests payer alignment may be building in parallel.

• Neogen–Zoetis Animal Genomics Deal: Neogen's announced $160M sale of its animal genomics business to Zoetis signals ongoing consolidation in the agricultural genomics space — worth watching for implications on livestock genomic data assets.